Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum.
about
A highly sensitive targeted mass spectrometric assay for quantification of AGR2 protein in human urine and serumApplications of targeted proteomics in systems biology and translational medicineAdvances in targeted proteomics and applications to biomedical researchMass spectrometry in cancer biomarker research: a case for immunodepletion of abundant blood-derived proteins from clinical tissue specimensBuilding a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease.Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society.Highly multiplexed and reproducible ion-current-based strategy for large-scale quantitative proteomics and the application to protein expression dynamics induced by methylprednisolone in 60 rats.Quantitative proteomics in cardiovascular research: global and targeted strategiesTowards identification of true cancer biomarkers.Antibody-independent targeted quantification of TMPRSS2-ERG fusion protein products in prostate cancer.Expediting SRM assay development for large-scale targeted proteomics experiments.Toward sensitive and accurate analysis of antibody biotherapeutics by liquid chromatography coupled with mass spectrometry.Protein analysis by shotgun/bottom-up proteomicsIdentification of a novel proteoform of prostate specific antigen (SNP-L132I) in clinical samples by multiple reaction monitoringAnalytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods.Sensitive targeted quantification of ERK phosphorylation dynamics and stoichiometry in human cells without affinity enrichment.Liquid phase based separation systems for depletion, prefractionation, and enrichment of proteins in biological fluids and matrices for in-depth proteomics analysis-An update covering the period 2011-2014.Quantitative Profiling of Protein Tyrosine Kinases in Human Cancer Cell Lines by Multiplexed Parallel Reaction Monitoring AssaysAdvances in Proteomic Technologies and Its Contribution to the Field of CancerCompensatory Islet Response to Insulin Resistance Revealed by Quantitative Proteomics.Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma.Protein target quantification decision tree.Deciphering the biological effects of acupuncture treatment modulating multiple metabolism pathways.The clinical impact of recent advances in LC-MS for cancer biomarker discovery and verification.The NINDS Parkinson's disease biomarkers program.Contributions of immunoaffinity chromatography to deep proteome profiling of human biofluidsTargeted quantification of low ng/mL level proteins in human serum without immunoaffinity depletionRatiometric Measurements of Adiponectin by Mass Spectrometry in Bottlenose Dolphins (Tursiops truncatus) with Iron Overload Reveal an Association with Insulin Resistance and GlucagonConnecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis ConsortiumConservation of protein abundance patterns reveals the regulatory architecture of the EGFR-MAPK pathwayLong-gradient separations coupled with selected reaction monitoring for highly sensitive, large scale targeted protein quantification in a single analysis.Comparison of protein immunoprecipitation-multiple reaction monitoring with ELISA for assay of biomarker candidates in plasma.Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometryTargeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach.Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag.Simplified and efficient quantification of low-abundance proteins at very high multiplex via targeted mass spectrometry.Targeted quantitation of CVD-linked plasma proteins for biomarker verification and validation.Pre-analytical and analytical variability in absolute quantitative MRM-based plasma proteomic studies.Technological advances for deciphering the complexity of psychiatric disorders: merging proteomics with cell biology.Proteomic and other analyses to determine the functional consequences of deregulated kallikrein-related peptidase (KLK) expression in prostate and ovarian cancer.
P2860
Q24307894-9CE16675-24EE-442C-A024-3E48EBFE9E60Q26852271-AAE8EFA0-A433-4F9A-AA25-9523C71BBBBFQ28066912-C0870903-3563-4362-B8AA-783F55B39B70Q28307595-4D683D43-1E7B-42B3-A74C-33520484F49BQ33745617-8AA9C18E-1315-4847-86CC-1AC15D89CDB8Q33850616-BAFF55E7-72AB-4F82-9854-11D9992301ABQ34070221-B207CFC6-3C19-4FB7-9E60-8465D1BFE814Q34156082-99FF1073-6AA3-4F5A-8D00-EF515AF12A04Q34168702-0D49DC99-4C81-4941-9696-1801B2F208B8Q34283031-5BE01248-9BBB-4942-9B6C-4B651377B2DBQ34286018-C533D975-D3D1-4271-931C-2307923AFE12Q34359998-701A6596-3B61-4B5B-A4DA-5EE75F064803Q34600986-849FD922-B5FD-4C0E-95FA-C82C39DD92ADQ34810177-82F39BC7-DA0E-45BE-A550-282ADFC39CE5Q35125405-F6B6EDC5-F3D4-4EB0-8492-374B275D18AFQ35193821-F205980E-EE14-45E5-B25A-75800E3FD882Q35799972-67A9790B-BCA2-4A03-824B-B223C772482EQ35859573-7CFE0E01-A48F-4D9B-8C16-61B56AFF9FDCQ36112651-AB3B6E5C-1DA4-40F0-B1C9-7FDC16108EDBQ36191447-2688A662-C3E6-4AEF-97FB-008223DE02EBQ36382143-FA3DDEDD-17DD-4187-AD49-D6E89F09FD48Q36582456-FD0ED899-B55E-4093-A3E5-F1AD5CBC3B39Q36583023-A5C803E7-4A18-4FC3-872F-5E1AE195EC94Q36771005-4F5C9D65-425D-4C16-B90F-497563B50468Q36777618-8EAA8168-08DE-4650-B540-4803B55F5016Q36889137-B89454A8-F437-422C-82B0-009E4327CCD0Q37069906-15434C21-921F-4AE6-83EB-2EA80E584245Q37186111-84DA9B11-F9EE-4247-93B2-6F3897AD9FBFQ37238264-2618382D-9262-45DF-AF30-77D7A54BFF9EQ37284069-F97E64AE-7DA2-4658-8F36-7D8AB7290CEAQ37341145-055E38F5-F28D-4309-9435-D2B592412F93Q37394942-824CBF36-C7FE-4CA8-BF0F-5397073B546EQ37618631-0F989D4C-8401-4BB5-9900-CC1CD569DD35Q37623655-F484C078-12B2-4665-B262-350295C6C0F7Q37635618-C2F8FBC7-9B2B-4A9A-BE2B-061C90D20EB5Q37687439-EC7803BC-8C80-4006-9001-862CB9AC5060Q38160931-446553E9-F635-4523-B843-39ADCA51BC69Q38164428-94A175F8-C3BF-4E52-AA7C-F7548E570EB1Q38187682-59013CBC-4BE7-49C4-8472-A1981430D19CQ38188878-DC023B16-862E-40D5-A703-65D18F9E851E
P2860
Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Antibody-free, targeted mass-s ...... levels in human plasma/serum.
@ast
Antibody-free, targeted mass-s ...... levels in human plasma/serum.
@en
type
label
Antibody-free, targeted mass-s ...... levels in human plasma/serum.
@ast
Antibody-free, targeted mass-s ...... levels in human plasma/serum.
@en
prefLabel
Antibody-free, targeted mass-s ...... levels in human plasma/serum.
@ast
Antibody-free, targeted mass-s ...... levels in human plasma/serum.
@en
P2093
P2860
P50
P356
P1476
Antibody-free, targeted mass-s ...... levels in human plasma/serum.
@en
P2093
David G Camp
Jacob Kagan
Jong-Seo Kim
Karin D Rodland
Ljiljana Pasa-Tolić
Mahmud Hossain
Nathan Jones
Ronald J Moore
P2860
P304
15395-15400
P356
10.1073/PNAS.1204366109
P407
P577
2012-09-04T00:00:00Z